Products & Portfolio (12)
BYOOVIZ
ranibizumab-nuna
Peak
mAbINJECTION · INJECTABLE
Vascular Endothelial Growth Factor Inhibitors
Macular Degeneration
2021
30
DENOSUMAB-DSSB
denosumab
Growth
mAbSUBCUTANEOUS · INJECTABLE
RANK Ligand Blocking Activity
postmenopausal women with osteoporosis at high risk for fracturedefinedmultiple risk factors for fracture+6 more
2025
30
EPYSQLI
eculizumab-aagh
Growth
mAbSOLUTION · INJECTION
Complement Inhibitors
generalized myasthenia gravis (gMG) in adult patientshemolysis
2024
30
ETICOVO
etanercept-ykro
Peak
INJECTION · INJECTABLE
2019
30
HADLIMA
adalimumab-bwwd
Peak
mAbINJECTION · INJECTABLE
Tumor Necrosis Factor Receptor Blocking Activity
2019
30
ONTRUZANT
trastuzumab
Peak
mAbIV (INFUSION) · POWDER
HER2/Neu/cerbB2 Antagonists
2019
30
OPUVIZ
aflibercept-yszy
Growth
INJECTION · INJECTABLE
2024
30
OSPOMYV
denosumab
Growth
mAbSUBCUTANEOUS · INJECTABLE
RANK Ligand Blocking Activity
2025
30
PYZCHIVA
ustekinumab-ttwe
Growth
mAbSUBCUTANEOUS · INJECTABLE
Interleukin-12 Antagonists
2024
30
PYZCHIVA
ustekinumab-ttwe
Growth
mAbINJECTION · INJECTABLE
Interleukin-12 Antagonists
2024
30
RENFLEXIS
infliximab
Peak
mAbINJECTION · INJECTABLE
Tumor Necrosis Factor Receptor Blocking Activity
2017
30
XBRYK
denosumab
Growth
mAbSUBCUTANEOUS · INJECTABLE
RANK Ligand Blocking Activity
2025
30
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Portfolio: 12 approved products
Top TAs: Immunology, Musculoskeletal, Oncology
Portfolio Health
Growth7 (58%)
Peak5 (42%)
12 total products
Therapeutic Area Focus
Immunology
4 marketed
Musculoskeletal
3 marketed
Oncology
3 marketed
Ophthalmology
1 marketed
Rare Diseases
1 marketed
Marketed
Pipeline